Effectiveness and Safety of Enteric-Coated vs Uncoated Aspirin in Patients With Cardiovascular Disease

医学 阿司匹林 心肌梗塞 内科学 冲程(发动机) 临床终点 加药 累积发病率 冠状动脉疾病 入射(几何) 比例危险模型 外科 随机对照试验 队列 工程类 物理 光学 机械工程
作者
Amber Sleem,Mark B. Effron,Amanda Stebbins,Lisa Wruck,Guillaume Marquis‐Gravel,Daniel Muñoz,Richard N. Ré,Kamal Gupta,Carl J. Pepine,Sandeep Jain,Saket Girotra,Jeff Whittle,Catherine P. Benziger,Peter Farrehi,Kirk U. Knowlton,Tamar S. Polonsky,Matthew T. Roe,Russell L. Rothman,Robert A. Harrington,W. Schuyler Jones,Adrian F. Hernandez
出处
期刊:JAMA Cardiology [American Medical Association]
卷期号:8 (11): 1061-1061 被引量:1
标识
DOI:10.1001/jamacardio.2023.3364
摘要

Clinicians recommend enteric-coated aspirin to decrease gastrointestinal bleeding in secondary prevention of coronary artery disease even though studies suggest platelet inhibition is decreased with enteric-coated vs uncoated aspirin formulations.To assess whether receipt of enteric-coated vs uncoated aspirin is associated with effectiveness or safety outcomes.This is a post hoc secondary analysis of ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness), a pragmatic study of 15 076 patients with atherosclerotic cardiovascular disease having data in the National Patient-Centered Clinical Research Network. Patients were enrolled from April 19, 2016, through June 30, 2020, and randomly assigned to receive high (325 mg) vs low (81 mg) doses of daily aspirin. The present analysis assessed the effectiveness and safety of enteric-coated vs uncoated aspirin among those participants who reported aspirin formulation at baseline. Data were analyzed from November 11, 2019, to July 3, 2023.ADAPTABLE participants were regrouped according to aspirin formulation self-reported at baseline, with a median (IQR) follow-up of 26.2 (19.8-35.4) months.The primary effectiveness end point was the cumulative incidence of the composite of myocardial infarction, stroke, or death from any cause, and the primary safety end point was major bleeding events (hospitalization for a bleeding event with use of a blood product or intracranial hemorrhage). Cumulative incidence at median follow-up for primary effectiveness and primary safety end points was compared between participants taking enteric-coated or uncoated aspirin using unadjusted and multivariable Cox proportional hazards models. All analyses were conducted for the intention-to-treat population.Baseline aspirin formulation used in ADAPTABLE was self-reported for 10 678 participants (median [IQR] age, 68.0 [61.3-73.7] years; 7285 men [68.2%]), of whom 7366 (69.0%) took enteric-coated aspirin and 3312 (31.0%) took uncoated aspirin. No significant difference in effectiveness (adjusted hazard ratio [AHR], 0.94; 95% CI, 0.80-1.09; P = .40) or safety (AHR, 0.82; 95% CI, 0.49-1.37; P = .46) outcomes between the enteric-coated aspirin and uncoated aspirin cohorts was found. Within enteric-coated aspirin and uncoated aspirin, aspirin dose had no association with effectiveness (enteric-coated aspirin AHR, 1.13; 95% CI, 0.88-1.45 and uncoated aspirin AHR, 0.99; 95% CI, 0.83-1.18; interaction P = .41) or safety (enteric-coated aspirin AHR, 2.37; 95% CI, 1.02-5.50 and uncoated aspirin AHR, 0.89; 95% CI, 0.49-1.64; interaction P = .07).In this post hoc secondary analysis of the ADAPTABLE randomized clinical trial, enteric-coated aspirin was not associated with significantly higher risk of myocardial infarction, stroke, or death or with lower bleeding risk compared with uncoated aspirin, regardless of dose, although a reduction in bleeding with enteric-coated aspirin cannot be excluded. More research is needed to confirm whether enteric-coated aspirin formulations or newer formulations will improve outcomes in this population.ClinicalTrials.gov Identifier: NCT02697916.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
香蕉觅云应助xuliangzheng采纳,获得10
2秒前
Hexagram发布了新的文献求助10
4秒前
yinggill完成签到 ,获得积分10
5秒前
帕丁顿发布了新的文献求助10
6秒前
6秒前
6秒前
真实的白翠完成签到,获得积分10
6秒前
汉堡包应助博士采纳,获得10
7秒前
温暖的沛凝完成签到 ,获得积分10
7秒前
醉熏的友卉完成签到,获得积分20
8秒前
万能图书馆应助夕夕口口采纳,获得10
8秒前
9秒前
9秒前
wenhao发布了新的文献求助10
10秒前
11秒前
jawa完成签到 ,获得积分10
11秒前
能干亦玉发布了新的文献求助10
11秒前
Orange应助guanghuawang采纳,获得10
12秒前
zhou完成签到,获得积分10
12秒前
kuoping完成签到,获得积分0
13秒前
14秒前
chen发布了新的文献求助10
14秒前
lelele发布了新的文献求助10
14秒前
科研通AI5应助Hexagram采纳,获得10
15秒前
15秒前
深情安青应助道松先生采纳,获得10
15秒前
KSDalton完成签到,获得积分10
15秒前
15秒前
tuanzi发布了新的文献求助10
16秒前
17秒前
pcr163应助仿生人采纳,获得100
18秒前
18秒前
xrL完成签到,获得积分10
18秒前
20秒前
HonamC完成签到,获得积分10
20秒前
星辰大海应助肯瑞恩哭哭采纳,获得10
20秒前
高中生完成签到,获得积分10
21秒前
ChrisKim发布了新的文献求助10
21秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Effective Learning and Mental Wellbeing 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976058
求助须知:如何正确求助?哪些是违规求助? 3520294
关于积分的说明 11202245
捐赠科研通 3256804
什么是DOI,文献DOI怎么找? 1798471
邀请新用户注册赠送积分活动 877610
科研通“疑难数据库(出版商)”最低求助积分说明 806496